

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

NCI-H2122

RRID:CVCL_1531

Type: Cell Line

Proper Citation

RRID:CVCL_1531

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1531

Proper Citation: RRID:CVCL_1531

Description: Cell line NCI-H2122 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:8806092](#), [PMID:10987304](#), [PMID:11030152](#), [PMID:11314036](#), [PMID:16157194](#), [PMID:16187286](#), [PMID:18083107](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24135919](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30038707](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2122

Synonyms: H2122, H-2122, NCIH2122

Cross References: BTO:BTO_0003006, CLO:CLO_0008055, EFO:EFO_0002279, AddexBio:C0016048/5013, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5985,

BioGRID_ORCS_Cell_line:531, BioSample:SAMN03473110, BioSample:SAMN10988248, cancercellines:CVCL_1531, Cell_Model_Passport:SIDM00702, ChEMBL-Cells:ChEMBL3308771, ChEMBL-Targets:ChEMBL1075533, CLS:305600, Cosmic:722046, Cosmic:850435, Cosmic:877252, Cosmic:877441, Cosmic:903615, Cosmic:1028947, Cosmic:1146902, Cosmic:1152517, Cosmic:1219086, Cosmic:1239891, Cosmic:1320182, Cosmic:1518085, Cosmic:1694665, Cosmic:1870269, Cosmic:1891901, Cosmic:1995559, Cosmic:2125195, Cosmic:2696405, Cosmic-CLP:722046, DepMap:ACH-000311, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:722046, GEO:GSM62330, GEO:GSM108837, GEO:GSM108838, GEO:GSM206484, GEO:GSM253371, GEO:GSM274751, GEO:GSM274752, GEO:GSM434253, GEO:GSM513957, GEO:GSM514342, GEO:GSM784219, GEO:GSM794353, GEO:GSM817102, GEO:GSM827526, GEO:GSM887407, GEO:GSM888486, GEO:GSM1374722, GEO:GSM1374723, GEO:GSM1670217, GEO:GSM2807227, GEO:GSM2807228, IARC_TP53:21556, IGRhCellID:NCIH2122, KCLB:92122, LiGeA:CCLE_056, LINCX_LDP:LCL-1651, PharmacDB:NCIH2122_1070_2019, PRIDE:PXD030304, Progenetix:CVCL_1531, PubChem_Cell_line:CVCL_1531, Wikidata:Q54907928

ID: CVCL_1531

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260905T181243+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2122.

No alerts have been found for NCI-H2122.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Shang X, et al. (2026) Dual PD-1/IL-2R γ targeting restores CD8⁺ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. Cell reports. Medicine, 7(3), 102633.

Suzuki S, et al. (2026) Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance. Cancer immunology research, 14(7), 1172.

Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. Immunity, 59(7), 1928.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. *Oncogene*, 45(31), 3244.

Brunner JS, et al. (2026) Aspartate availability drives differential engagement of the malate-aspartate shuttle. *Molecular cell*, 86(5), 954.

Kanemura H, et al. (2026) Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors. *Cancer research communications*, 6(4), 728.

Horvat NK, et al. (2026) Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer. *Cancer immunology research*, 14(6), 974.

Jameson NM, et al. (2025) The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. *Cancer research communications*, 5(2), 240.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Maso L, et al. (2025) Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy. *Nature communications*, 16(1), 11264.

Sasaki N, et al. (2025) RNA sensing induced by chromosome missegregation augments anti-tumor immunity. *Molecular cell*, 85(4), 770.

Wang Y, et al. (2025) Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. *Cancer research*, 85(11), 1997.

Lu S, et al. (2025) Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. *Molecular cancer therapeutics*, 24(6), 920.

Geburu MT, et al. (2025) Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer. *Cancer research*, 85(23), 4806.

Paulsohn MB, et al. (2025) Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. *Cell death & disease*, 17(1), 129.

Shan W, et al. (2025) Combined inhibition of hexokinase 2 and pyruvate dehydrogenase surmounts SHP2 inhibitor resistance in non-small cell lung cancer with hybrid metabolic state harboring KRAS Q61H mutation. *Biochimica et biophysica acta. Molecular basis of disease*, 1871(6), 167859.

Ibáñez-Molero S, et al. (2024) Phosphoprotein dynamics of interacting T cells and tumor cells by HySic. *Cell reports*, 43(1), 113598.

Takaki EO, et al. (2024) A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. *Clinical cancer research : an*

official journal of the American Association for Cancer Research, 30(16), 3603.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Wu PY, et al. (2024) Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men. *iScience*, 27(2), 108858.